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Abstract 
Breast cancer is one of the most commonly diagnosed cancers in women worldwide. Approximately 40% 
of patients with breast cancer acquire endocrine resistance following therapy with tamoxifen. Many 
explanations for the development of endocrine resistance have been put forward, one of them being the 
dysregulation of long non-coding RNAs (lncRNAs). The lncRNA HOTAIRM1, known to be involved in 
myelopoiesis as well as transcriptional regulation of the HOXA genes in embryonic stem cells, is also 
expressed in breast cancer cells. This study explored the molecular mechanisms of HOTAIRM1 involved 
in acquired tamoxifen resistance. We showed that HOTAIRM1 and HOXA1 are concurrently 
up-regulated in tamoxifen-resistant MCF7 (TAMR) cells. Knockdown of HOTAIRM1 down-regulated 
HOXA1 expression and restored sensitivity to tamoxifen. In addition, the knockdown of HOXA1 
showed similar effects, suggesting that the HOTAIRM1/HOXA1 axis regulates tamoxifen resistance. 
Furthermore, we showed that HOTAIRM1 directly interacts with EZH2 and prevents the PRC2 complex 
from binding and depositing H3K27me3 on the putative promoter of HOXA1. Together, our findings 
suggest that HOXA1 and its neighboring lncRNA, HOTAIRM1, might serve as potential therapeutic 
targets for ER+ breast cancer patients who have acquired tamoxifen resistance. 
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Introduction 
Breast cancer is the most commonly diagnosed 
cancer in women, with the estrogen-receptor positive 
(ER+) subtype being the most prevalent [1-3]. Patients 
with ER+ cancer are generally treated with selective 
estrogen-receptor modulators (SERMs), such as 
tamoxifen [4,5]. Patients initially respond to 
tamoxifen, but many eventually develop resistance to 
tamoxifen, ultimately leading to relapsed or 
metastatic breast cancer [6-8]. Although there are 
extensive studies on the mechanisms underlying the 
development of tamoxifen resistance, there is still a 
lack of practical molecular markers to predict 
tamoxifen resistance and/or breast cancer recurrence. 
Therefore, it is imperative to identify novel 
biomarkers for tamoxifen resistance. 
 The homeobox (HOX) genes are a group of 39 
genes organized into 4 different clusters: HOXA, B, C, 
and D. The HOX family plays key roles during 
embryogenesis by regulating various cellular and 
physiological processes [9-11]. More recently, 
numerous HOX genes have been reported to act as 
oncogenes or tumor suppressors [12-14]. For example, 
HOXA1 has been found to induce tumorigenesis in 
multiple types of cancers such as breast, lung, and 
gastric cancers [15-18]. Nevertheless, the role of 
HOXA1 and its role in tamoxifen-resistant breast 
tumors have not yet been defined. 
Emerging evidence suggests that long 
non-coding RNAs (lncRNAs), defined as RNA 








incapable of encoding proteins, play crucial roles in 
transcriptional and post-transcriptional regulation, 
microRNA sponging, as well as chromatin 
remodeling [19-21]. More recently, the functions and 
mechanisms of lncRNAs in cancer have been 
receiving research attention, and a number of 
lncRNAs have been reported to be involved in 
endocrine resistance, as well as breast cancer 
progression and metastasis [22-24]. Within the HOXA 
cluster is a long non-coding RNA, HOTAIRM1, 
located between HOXA1 and HOXA2. The role of 
HOTAIRM1 as an oncogenic factor has been 
described in several cancers [25,26], and the function 
of HOTAIRM1 as a regulator of the oncogene HOXA1 
has been previously described in glioblastoma 
multiforme [26]. However, the regulatory role of 
HOTAIRM1 on HOXA1 transcription in breast cancer, 
more specifically tamoxifen-resistant breast cancer, 
remains unknown. 
 In the present study, we showed that the 
lncRNA HOTAIRM1 is upregulated in tamoxifen- 
resistant breast cancer cells (TAMR), compared to 
levels in ER+ breast cancer cells (MCF7). HOXA1 was 
also shown to be upregulated in TAMR cells. 
Knockdown of HOTAIRM1 or HOXA1 could 
re-sensitize TAMR cells to tamoxifen treatment, 
suggesting that the HOTAIRM1/HOXA1 axis 
contributes to tamoxifen resistance in breast cancer. 
More notably, HOTAIRM1 could directly interact 
with EZH2 and prevent EZH2 from binding to the 
putative promoter of HOXA1, ultimately activating 
HOXA1 transcription. Our results revealed a novel 
mechanism which demonstrates that HOTAIRM1 and 
HOXA1 could be promising therapeutic targets for 
patients with ER+ breast cancer who have acquired 
tamoxifen resistance. 
Materials and Methods 
Cell lines and culture 
MCF7, T47D, MCF7-TAMR, and T47D-TAMR 
cells were used. MCF7-TAMR cells were generated as 
an in vitro  model for acquired tamoxifen resistance by 
exposing MCF7 cells to long-term 1 μM 
4-hydroxytamoxifen (Sigma, MO, USA) treatment 
[27]. T47D and T47D-TAMR cells (T47D/S2 [152109], 
T47D/TR-1 [152108], and T47D/TR-2 [152110]) 
obtained from Ximbio were kindly provided by Dr. 
Mi-Ock Lee (Seoul National University). MCF7 and 
MCF7-TAMR cell lines were cultured in Dulbecco’s 
modified Eagle medium (WelGENE Inc., Daegu, 
Korea). The medium was supplemented with heat- 
inactivated 10% FBS (WelGENE Inc.) and penicillin- 
streptomycin (WelGENE Inc.). T47D cells were 
maintained in RPMI 1640 (WelGENE Inc.) with the 
same supplementation. T47D-TAMR cells were 
cultured in Phenol Red-free RPMI 1640 (WelGENE 
Inc.) containing 2% FBS, 2 mM Glutamax (Thermo 
Fisher Scientific, MA, USA), 8 μg/mL human insulin 
(WelGENE Inc.), and 1% penicillin streptomycin. Both 
tamoxifen-resistant cells were cultured in medium 
containing 1 μM 4-hydroxytamoxifen. Cells were 
grown at 37 °C in a 5% CO2 incubator. 
Total RNA isolation and RT-PCR 
Total RNA was extracted from cells using TRIzol 
reagent (Invitrogen, CA, USA), and cDNA was 
synthesized with 1 μg of total RNA using 
ImProm-IITM Reverse Transcriptase (Promega, WI, 
USA). PCR amplification was performed under the 
following conditions: initial denaturation for 5 mins at 
94 °C, followed by 27-35 cycles of 94 °C for 40 sec 
(depending on target gene), 58°C for 20 sec, and 72 °C 
for 30 sec. For quantitative PCR, a StepOnePlus 
Real-Time PCR System (Applied Biosystems, CA, 
USA) and Power SYBR Green PR Master Mix 
(Applied Biosystems) were used. All PCR reactions 
were performed in at least three independent 
biological replicates, and β-Actin and GAPDH were 
used as internal controls. PCR primers are listed in 
Table 1. 
 
Table 1. List of primers used for PCR and ChIP-PCR 


















































siRNA and transfection 
Knockdown studies were performed by 
transfecting TAMR cells for 48 hours with 20 nM 
siHOTAIRM1 or 40 nM siHOXA1 using G-fectin 
(Genolution, Seoul, Korea) following the 
manufacturer’s protocol. A pool of 4 individual 




siRNAs targeting exons 1 and 3 of HOTAIRM1, and a 
single siRNA targeting exon 2 of HOXA1 were used 
(Supplementary Table 1). siRNAs were designed and 
purchased from Genolution.  
Cell proliferation assay 
Relative cell proliferation was measured using a 
Cell Counting Kit-8 (Dojindo Molecular Technologies 
Inc., Kumamoto, Japan) following the manufacturer’s 
protocol. Briefly, 7.5 × 103 cells/well were plated and 
grown on 96-well plates, stained with 10 μL of WST-8, 
and reacted for 3 hours at 37 °C in a 5% CO2 incubator 
for three consecutive days. The plate was then 
analyzed using a Softmax Pro microplate reader 
(Molecular Devices, CA, USA) at an absorbance of 450 
nm. 
Chromatin immunoprecipitation (ChIP) 
analysis 
ChIP analysis was performed as previously 
described with minor modifications [28]. Briefly, cells 
were fixed with 1% formaldehyde for 15 mins at room 
temperature, and then quenched with 2.5 M glycine. 
Cells were lysed on ice for 10 mins in SDS buffer 
containing protease inhibitors, and then sonicated 
with a Sonics Vibra CellTM (6 mins: pulse 10 sec, 
interval 10 sec) on ice. The fragmented chromatin 
samples were centrifuged at 8000 × g at 4 °C for 5 mins 
and supernatant was collected. The samples were 
pre-cleared, and then incubated overnight at 4 °C with 
appropriate antibodies and protein-coated A/G 
agarose beads (Santa Cruz, CA, USA) with gentle 
shaking. The immunoprecipitated eluates were 
reverse cross-linked and recovered through DNA 
purification for PCR. Anti-H3K4me3 (Abcam, 
ab1012), anti-H3K9ac (Abcam, ab12179), anti- 
H3K27me3 (Abcam, ab6002), anti-EZH2 (Cell 
Signaling, 5246S), and non-immune mouse IgG (Santa 
Cruz, sc2025) antibodies were used. ChIP-PCR 
primers are listed in Table 1. 
RNA immunoprecipitation (RIP) analysis 
RIP analysis was performed as previously 
described with minor modifications [29]. Briefly, 1 × 
107 cells/antibody were collected and lysed on ice in 
RIP buffer containing protease inhibitors for 10 mins, 
then sonicated with a Sonics Vibra CellTM (5 mins: 
pulse 10 sec, interval 10 sec) on ice. The lysates were 
centrifuged at 12,000 × g at 4 °C for 5 mins and the 
supernatant was taken. The samples were first 
incubated with anti-EZH2 (5246S) and non-immune 
mouse IgG (sc2025) antibodies at 4 °C for at least 4 
hours, and then protein-coated A/G agarose beads 
(Santa Cruz, CA, USA) were added and incubated 
overnight at 4 °C with gentle shaking. On the 
following day, the immunoprecipitated eluates were 
resuspended in 1 mL TRIzol, and RNA was extracted. 
The desired product was detected by PCR with 
primers listed in Table 1. 
In silico analysis 
The TANRIC web-accessible database was used 
to evaluate the correlation between HOTAIRM1 and 
HOXA1 mRNA expressions in patients’ breast cancer 
tissues and various breast cancer cell lines 
(https://ibl.mdanderson.org/tanric/_design/basic/i
ndex.html). The TANRIC database is generated using 
the Cancer Genome Atlas (TCGA) data portal and the 
Cancer Cell Line Encyclopedia (CCLE). 
Statistical analysis 
Data are expressed as the mean ± SD. Statistical 
differences were determined using Student’s t-test for 
a pairwise comparison. p-values < 0.05 were 
considered significant. 
Results 
HOTAIRM1 is associated with tamoxifen 
resistance in MCF7 cells 
First, we examined the expression level of 
HOTAIRM1 between ER+ breast cancer cells (MCF7 
and T47D) and tamoxifen-resistant breast cancer cells 
(TAMR) by RT-qPCR. Our result shows that the 
expression of HOTAIRM1 was significantly 
up-regulated in TAMR cells (Fig. 1A and Fig. S1A). To 
explore the role of HOTAIRM1 in tamoxifen 
resistance, we transiently transfected TAMR cells with 
siHOTAIRM1, and confirmed a notable reduction in 
HOTAIRM1 level (Fig. 1B and Fig. S1B). The cell 
viability of these knockdown cells in the absence and 
presence of high-dose tamoxifen (12 μM) was 
measured and compared. In the absence of tamoxifen, 
knockdown of HOTAIRM1 did not result in much 
difference in cell proliferation in comparison to that in 
control cells. Interestingly, a significant re- 
sensitization to tamoxifen treatment was observed in 
HOTAIRM1-depleted TAMR cells compared to 
siCON-treated and parent TAMR cells (Fig. 1C and 
Fig. S1C). Taken together, these data suggest that 
HOTAIRM1 is associated with tamoxifen resistance in 
ER+ breast cancer cells. 
HOTAIRM1 promotes tamoxifen resistance 
via regulating HOXA1 expression 
HOTAIRM1 is intergenically positioned in 
between HOXA1 and HOXA2 at the promoter region 
of the HOXA1 gene (Fig. 2A). Since there are 
numerous reports on the function of lncRNAs as 
regulators of neighboring genes [22,24], we also 
preferentially examined the expression of genes 
surrounding HOTAIRM1. To confirm the association 




of HOTAIRM1 and HOXA1 expression in breast 
cancer, we first exploited TANRIC, an in silico 
database for lncRNAs in cancer, and found that the 
expression of HOTAIRM1 and HOXA1 is positively 
correlated in both human breast cancer tissues 
(TCGA, r= 0.719, p= 5.65e-131) and human breast 
cancer cell lines (CCLE, r = 0.842, p= 1.26e-13) (Fig. 2B 
and 2C).  
Since the positive correlation between 
HOTAIRM1 and HOXA1 was confirmed through in 
silico analysis, we performed RT-qPCR in our model 
cell lines to explore this association. We confirmed 
that HOXA1 is most significantly overexpressed in 
TAMR cells. The more anterior genes such as HOXA2 
and HOXA3 were also comparatively upregulated, 
whereas the expression levels of the other HOXA 
genes remained similar between MCF7 and TAMR 
cells (Fig. 2D). In addition, this gene expression 
pattern was also observed in breast cancer tissues 
through HOTAIRM1-mRNA correlation analysis 
using TCGA data retrieved from TANRIC (Fig. S2). 
To examine whether HOTAIRM1 functions as a 
regulator of the adjacent HOXA1 gene transcription in 
tamoxifen-resistant breast cancer cells, we treated 
TAMR cells with siHOTAIRM1 and examined the 
expression of anterior HOXA genes. Surprisingly, 
upon knockdown of HOTAIRM1, only the expression 
of HOXA1 was reduced, while the expression of 
HOXA2 to HOXA9 was unchanged (Fig. 2E). The 
exclusive down-regulation of HOXA1 upon 
HOTAIRM1 knockdown was also observed in T47D- 
TAMR cells (Fig. S3A). These data indicate that 
HOTAIRM1 exclusively regulates the transcription of 
HOXA1.  
To further confirm whether tamoxifen resistance 
is modulated by HOTAIRM1-mediated HOXA1 
transcription, we transiently transfected TAMR cells 
with siHOXA1 (Fig. 2F and Fig. S3B). Their 
proliferation rates were not altered in the absence of 
tamoxifen, but in the presence of tamoxifen, a 
significant reduction in cell viability was observed 
compared to that of control cells (Fig. 2G and Fig. 
S3C). Collectively, it seems highly likely that 
resistance to tamoxifen is developed through the 
HOTAIRM1/HOXA1 axis and that sensitivity to 
tamoxifen can be reverted by depleting HOTAIRM1 
or HOXA1.  
HOTAIRM1 mediates HOXA1 expression 
through epigenetic modifications 
Epigenetic modifications and reprogramming by 
chromatin remodeling factors such as the PRC2 
 
 
Figure 1. HOTAIRM1 is associated with tamoxifen resistance in MCF7 cells. (A) RT-qPCR analysis of HOTAIRM1 in MCF7 and tamoxifen-resistant breast cancer 
(TAMR) cells. (B) RT-qPCR analysis of HOTAIRM1 in TAMR cells transiently transfected with pooled siHOTAIRM1 for 24 hours. GAPDH was used to normalize changes in 
HOTAIRM1 expression levels. (C) Cell viability curve of cells treated with siHOTAIRM1 in the absence (No Tam.– left panel) and presence of 12 µM tamoxifen (Tam.– right 
panel) at days 1, 2, and 3. All experiments were performed in triplicate. *** p < 0.001 compared with siCON by Student’s t-test. 




complex are well reported in the HOX clusters. More 
recently, the roles of lncRNAs in recruiting epigenetic 
modifiers in cancer are continuously being explored 
[30,31]. To study histone modifications and their 
impact on gene regulation, we first identified the 
putative promoter of HOXA1 by analyzing RNA 
Polymerase II and H3K4me3 enrichment marks (Fig. 
3A). Then, we compared the distribution of histone 
modification patterns such as H3K4me3, H3K9ac, and 
H3K27me3 between MCF7 and TAMR cells at this 
promoter region. H3K4me3 and H3K9ac marks were 
enriched at similar levels in both MCF7 and TAMR 
cells. Nevertheless, H3K27me3 repressive marks were 
significantly diminished in TAMR cells compared to 
MCF7 cells. Moreover, EZH2, a H3K27 
methyltransferase, was evidently less enriched in 
TAMR cells (Fig. 3B). This decrease in H3K27me3 and 
EZH2 explains the higher mRNA levels of 
HOTAIRM1 and HOXA1 in TAMR cells. 
Previous studies have shown that lncRNAs are 
capable of sequestering epigenetic regulators from 
their targets by competitively binding to them. To 
investigate whether HOTAIRM1 has a role in 
regulating H3K27me3 marks by disabling the 
recruitment of the PRC2 complex, we performed the 
identical ChIP assay after knockdown of HOTAIRM1 
in TAMR cells. In the presence of HOTAIRM1 (siCON 
sample), EZH2 binding at the putative promoter 
region of HOXA1 was almost undetectable; however, 
in HOTAIRM1-depleted TAMR cells, EZH2 marks 
returned, implicating that HOTAIRM1 interferes with 
the recruitment of the PRC2 complex to the promoter 
region. Along with EZH2, H3K27me3 marks were 
increased in the HOTAIRM1-depleted TAMR cells, 
further clarifying the role of HOTAIRM1 as a 
competitive interacting partner of EZH2 (Fig. 3C).  
 
 
Figure 2. HOTAIRM1 promotes tamoxifen resistance by regulating HOXA1 expression. (A) Schematic depiction of the HOTAIRM1/HOXA1 locus on human 
chromosome 7. Boxes represent exons, lines represent introns, and arrows show the direction of transcription. (B) Correlation curve between HOTAIRM1 and HOXA1 
expression in the TCGA breast cancer tissue database. (C) Correlation curve between HOTAIRM1 and HOXA1 in CCLE breast cancer cell line database. (D) RT-qPCR analysis 
of HOXA genes in MCF7 and tamoxifen-resistant breast cancer (TAMR) cells. (E) RT-PCR analysis of HOXA genes in TAMR cells transiently transfected with pooled 
siHOTAIRM1 for 24 hours. (F) RT-PCR of HOXA1 and HOTAIRM1 in TAMR cells transiently transfected with siHOXA1 for 24 hours. (G) Cell viability curve of cells treated 
with siHOXA1 or control siCON in the absence (No Tam.– left panel) and presence of 12 µM tamoxifen (Tam.– right panel) at days 1, 2, and 3. TAMR parent cells were included 
as a control without any siRNA treatment. GAPDH was used to normalize changes in the mRNA levels of interest in panel (D). β-Actin was used as an internal control in panels 
(E) and (F). All experiments were performed in triplicate. *** p < 0.001 compared with siCON by Student’s t-test. 





Figure 3. HOTAIRM1 mediates HOXA1 expression through epigenetic modifications. (A) Diagram representing the HOTAIRM1/HOXA1 promoter region in 
MCF7 cells. RNA Pol II and H3K4me3 ChIP-seq data retrieved from ENCODE. The red bar represents the amplicon site used in ChIP-PCR. (B) ChIP-PCR analysis of H3K4me3, 
H3K9ac, H3K27me3, and EZH2 in MCF7 and tamoxifen-resistant breast cancer (TAMR) cells. (C) ChIP-PCR analysis of H3K27me3 and EZH2 in HOTAIRM1-knockdown TAMR 
cells. All experiments were performed in triplicate. 
 
HOTAIRM1 directly interacts with EZH2 and 
hinders the deposition of H3K27me3 marks at 
the putative HOXA1 promoter 
To define whether HOTAIRM1 regulates EZH2 
expression at the transcriptional level or affects the 
deposition of methyl marks at H3K27 by interacting 
with pre-existing EZH2, we first examined and 
compared the mRNA and protein expression levels of 
EZH2 between MCF7 and TAMR cells. The mRNA 
and protein levels of EZH2 were comparable between 
the two cell lines (Fig. 4A). Likewise, even upon 
siHOTAIRM1 treatment, the expression levels of 
EZH2 in both mRNA and protein forms were 
unchanged, implying that HOTAIRM1 does not have 
any effect on regulating the expression of EZH2 (Fig. 
4B). Therefore, we hypothesized that HOTAIRM1 
may have a role in modulating the binding affinity of 
EZH2 at the putative HOXA1 promoter region. To 
validate our hypothesis, we performed a RIP assay to 
see whether HOTAIRM1 and EZH2 form a complex, 
and if there is any variance in the interaction 
frequency between MCF7 and TAMR cells. 
Remarkably, HOTAIRM1 and EZH2 formed direct 
interactions in TAMR cells, while there was no 
presence of direct binding between HOTAIRM1 and 
EZH2 in MCF7 cells (Fig. 4C). These results indicate 
that in tamoxifen-resistant breast cancer cells, 
HOTAIRM1 complexes with EZH2, preventing the 
enzyme from binding to the putative promoter of 
HOXA1 to deposit repressive H3K27me3 marks. 
Discussion 
Here, we propose that HOTAIRM1, a highly 
expressed lncRNA in tamoxifen-resistant breast 
cancer cells, is a novel marker for tamoxifen 
resistance. The overexpressed HOTAIRM1 results in 
the up-regulation of its target gene, HOXA1, and is 
accompanied by an increase of tamoxifen resistance. 
Conversely, upon transient knockdown of 
HOTAIRM1, the expression of HOXA1 was 
concomitantly reduced, and sensitivity to tamoxifen 
treatment was restored. More importantly, we 
discovered that HOTAIRM1 inhibits the PRC2 
complex from binding to the HOXA1 promoter region 
in TAMR cells by forming a direct interaction with 
EZH2, resulting in the higher expression of HOXA1.  
 Previous studies have identified HOTAIRM1 as 
a key lncRNA biomarker in several solid tumors, as 
well as in leukemia, by acting as tumor suppressors or 
oncogenes. For example, in hepatocellular carcinoma 
and gastric cancer, HOTAIRM1 prevents cancer 
progression by suppressing signaling cascades such 




as the Wnt and the PI3K/AKT pathways [32,33]. On 
the other hand, high expression of HOTAIRM1 has 
been associated with oncogenicity in pancreatic ductal 
carcinoma by promoting proliferative and migratory 
abilities [25]. In addition, the role of HOTAIRM1 in 
occluding epigenetic factors like G9a and EZH2, and 
reducing repressive histone enrichments have been 
reported in glioblastoma multiforme [26]. 
Nevertheless, no study has been conducted to 
investigate the role of HOTAIRM1 in drug resistance 
in breast cancer. 
Our study focused on the mechanism by which 
HOTAIRM1 regulates HOXA1 in tamoxifen-resistant 
breast cancer cells. We showed that HOTAIRM1 
hinders the catalytic activity of EZH2, an enzymatic 
component of the PRC2 complex, at the putative 
promoter region of HOXA1, resulting in 
demethylation of H3K27 in TAMR cells. More 
specifically, our RIP results further confirmed that 
HOTAIRM1 impedes the function of EZH2 through 
direct interaction, preventing EZH2 from binding and 
depositing methyl marks on H3K27 at the HOXA1 
promoter region. To further validate the clinical 
relevance of HOTAIRM1 and HOXA1, we analyzed a 
publicly available clinical in silico dataset comparing 
60 paired primary ER+ breast cancer patients to 
recurred cancer patients following tamoxifen mono- 
therapy for 5 years (GSE1379). Similar to our in vitro 
results, the expression of HOTAIRM1 and HOXA1 
were up-regulated in the recurred cancer patient 
group (Fig. S4), supporting our conclusion that 
HOTAIRM1 and HOXA1 are prospective indicators 
for tamoxifen resistance.  
HOTAIRM1 has 2 transcript variants with 2 or 3 
exons, with the first and last exons being shared. This 
lncRNA seems to undergo alternative splicing, and a 
previous study reporting on the role of HOTAIRM1 in 
the regulation of temporal collinear activation of 
HOXA genes in embryonic stem cells showed the 
major isoform to be the spliced form with all 3 exons 
[34]. On the contrary, in our breast cancer model 
system, we found that the spliced form with exons 1 
and 3 was the predominant form. Similarly, in acute 
myeloid leukemia (AML), the spliced form containing 
exons 1 and 3 was shown to be more prominent 
[34,35]. In both our system and the AML model, the 
spliced form containing exon 2 could not be detected. 
This phenomenon would be of great interest to 
investigate among different cell and tissue types, as 
different isoforms may have different cellular and 
physiological functions. 
Our study reveals for the first time that 
HOTAIRM1 is not only involved in cancer 
progression, but is also a marker of tamoxifen 
 
Figure 4. HOTAIRM1 directly interacts with EZH2 and hinders the deposition of H3K27me3 marks at the putative HOXA1 promoter. (A) RT-PCR and 
western blot showing RNA and protein levels of EZH2 in MCF7 and tamoxifen-resistant breast cancer (TAMR) cells. (B) RT-PCR and western blot showing RNA and protein 
levels of EZH2 in HOTAIRM1-knockdown TAMR cells. β-Actin was used as an internal control. (C) RIP-PCR analysis for the interaction between HOTAIRM1 and EZH2 in 
MCF7 and TAMR cells. U2snRNA was used as a negative control, and HOTAIR was used as a positive control. All experiments were performed in triplicate. 
 




resistance in breast cancer. HOTAIRM1 regulates 
HOXA1, and by doing so, contributes to an acquired 
tamoxifen resistance. The overexpression of 
HOTAIRM1 and/or HOXA1 could be potential 
biomarkers for tamoxifen resistance in patients 
receiving or that have received adjuvant tamoxifen 
therapy. Moreover, inhibitors of HOTAIRM1 and/or 
HOXA1 represent a possible therapeutic strategy to 
restore sensitivity in patients that have acquired 
tamoxifen resistance. Further exploration of the 
molecular mechanisms of the HOTAIRM1/HOXA1 
axis may provide more insight in the pathogenesis of 
breast cancer. 
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